3 Nuclear Energy Stocks to Buy Before 2026

Cameco is highlighted as a vertically integrated uranium supplier with high‑grade Canadian mines, stakes in Kazakhstan and Australian deposits, Ontario refinery and conversion facilities, and a 49% ownership of Westinghouse. Centrus currently sources LEU (including Russian TENEX under a waiver through 2027), faces a 2028 phaseout that will require replacing ~25% of enriched uranium imports, and aims to scale Piketon enrichment to produce LEU and HALEU using advanced centrifuges — it is the only NRC‑licensed HALEU producer for commercial and national security uses, contingent on DOE funding and customer commitments. Constellation is the largest U.S. nuclear operator with 22 GW fleet capacity and a ~94.6% capacity factor, has expanded via a $27 billion Calpine acquisition, is restarting Three Mile Island Unit 1, and has secured 20‑year PPAs with hyperscalers including Microsoft and Meta.

Analysis

Market structure: The immediate winners are vertically integrated players (CCJ) and enrichment/IP holders (LEU/Centrus, Westinghouse via BEP) because they capture mining, conversion, and enrichment spreads as Western buyers disgorge Russian TENEX supplies (25% of enriched uranium to be replaced by 2028). Large operators with contracted revenue (CEG: 22 GW, 94.6% capacity factor) gain pricing power and PPA optionality versus merchant generators. Pure-play spot miners without downstream capabilities are most exposed to price volatility and contract repricing.

Risk assessment: Key tail risks are regulatory/licensing delays (NRC for HALEU and Piketon expansion), a geopolitical thaw that restores Russian LEU flows, and operational setbacks/cost overruns in enrichment capex. Immediate effects are event-driven (DOE awards, PPA announcements in days–months); structural effects (HALEU market formation, replacement of 25% Russian LEU) play out 2026–2030. Hidden dependency: DOE funding and long-term customer contracts are binary catalysts for Centrus’ value realization.

Trade implications: Favor longs in integrated miners/enrichment (CCJ, LEU) and utilities with contracted nuclear (CEG); expect upward pressure on UX/URA and potential widened credit issuance for utility capex (modest upward pressure on investment-grade utility spreads). Use limited-duration call spreads on LEU to express DOE-funding upside and buy-and-hold positions in CEG for stable cashflows; consider pair trades long enrichment/IP vs short URA to separate spot from contractual enrichment value.

Contrarian angles: The market underestimates execution risk and historical precedent (2007–11 uranium cycle) where sentiment outran delivery — HALEU commercialization timelines may slip 12–36 months. There is a realistic scenario where spot uranium rallies are already priced in but enrichment capacity remains constrained, creating dispersion: integrated names rerate higher while spot-exposed ETFs correct. Rapid capex to fill gaps can drive dilution for smaller players, compressing near-term returns.

Key Decisions for Investors

• Establish a 2–3% long position in Cameco (CCJ) within 30 trading days to capture integrated-margin upside; set a 12–24 month target of +30–50% and a tactical stop-loss at -20% to control operational/regulatory risk.
• Initiate a speculative 1–1.5% position in Centrus (LEU) via a Jan‑2027 bull call spread (cost-limited) to express upside from DOE funding and Piketon expansion; increase to 3% only if DOE awards ≥$200–300M or NRC clears a key licensing milestone within 6 months.
• Buy a 2% position in Constellation Energy (CEG) for stable contracted cashflows and PPA optionality; consider writing one-year covered calls to enhance yield if share price appreciates >15% and add another 1% on any >8% pullback.
• Execute a relative-value pair: long CCJ (2% notional) vs short URA (1.5% notional) to hedge spot-uranium volatility while capturing enrichment and conversion premiums; rebalance if the CCJ/URA spread moves >15% or either leg moves >20% against the position.
• If holding concentrated nuclear exposure, buy 12‑month 15% OTM puts sized 0.5% of portfolio on CCJ/LEU as downside insurance; initiate if regulatory delays exceed 6 months or DOE funding is deferred beyond the next 90 days.